Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 282

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 282
---
 value per each Ordinary Share and preferred share. |

| D. | In April 2025,                                                                                 
 the Company entered into bridge loan agreements (the “April 2025 Loans” or “April              
 2025 Loan Agreements”), pursuant to which the Company obtained bridge loans from the           
 lenders thereto including certain related parties, including the Company’s chairman of the     
 board of directors, a member of the Company’s board of directors, and a director nominee.      
 The April 2025 Loans shall bear interest at 8% per annum until maturity and the Company agreed 
 to pay the lenders an additional risk premium equal to 50% of their respective loan amount.    |

The April 2025 Loan’s maturity date is
the earlier of August 31, 2025, or the date of consummation of a Qualified IPO. Furthermore, upon the occurrence of a Qualified IPO,
the April 2025 Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to two times their respective
loan amount in addition to the risk premium based on a price per share equal to 75% of the lowest price per share of the Ordinary Shares
during the first five trading days following the consummation of such IPO.

| E. | On                                                                                             
 July 1, 2025, the Company entered into amendments of the Bridge Loans, the January 2024 Loan,  
 the December 2024 Loan Agreement and the April 2025 Loan Agreements such that the lenders      
 party thereto shall be granted with a fixed number of warrants to purchase such number of      
 Ordinary Shares following the consummation of a Qualified IPO, in amounts of 140,000 warrants, 
 61,539 warrants, 55,224 warrants and 92,309 warrants, respectively.                            |

| F. | Regarding settlement              
 agreement with CSL, see Note 9.5. |

<div align='center'>F-30</div>

REGENTIS BIOMATERIALS LTD.

INTERIM CONDENSED BALANCE SHEETS

U.S. dollars in thousands (except share and per share data)

| Assets                                                                                                                              
 Current assets:                                                                                                                     |     | Note |   |     | As of     
 June 30,  
 2025      
 Unaudited |         |   |     | As of        
 December 31, 
 2024         
 Audited      |         |   |
|:------------------------------------------------------------------------------------------------------------------------------------|:----|:-----|--:|:----|